Online Fatigue Management Feasible, Effective for Multiple Sclerosis

sleep computer insomnia
sleep computer insomnia
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Self-guided, online, therapy-based interventions may be effective in improving symptoms of fatigue in patients with multiple sclerosis (MS), according to the results of a study reported in the Journal of Neurology, Neurosurgery, and Psychiatry

Fatigue is significantly disabling in patients with MS. Therapy may be used in management; however, patients are often limited from participation in one-on-one, office-based appointments due to their symptoms, costs, and the availability of qualified professionals.     

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies. 

Patients were recruited online through the German MS society website and randomly assigned (1:1) to one of two groups: ELEVIDA (n=139, 82% female, median patient determined disease steps (PDDS) 3.0) or waitlist control group (n=136, 79% female, median PDDS 3.0). Outcomes were measured at baseline, post-intervention (week 12), and follow-up (week 24). 

The primary end point of this study was performance on the Chalder Fatigue Scale. Patients in the ELEVIDA group demonstrated significantly decreased scores by week 12 (intention-to-treat analysis: between-group mean difference 2.74 points; 95% CI, 1.16-4.32; P =.0007; effect size d=0.53), which were sustained through week 24 (intention-to-treat analysis; between-group mean difference 2.19 points; 95% CI, 0.57-3.82; P =.0080).

Several secondary end points were also assessed. Those that reached thresholds of significance by week 12 included decrease in anxiety (P =.0406), and increases in quality of life in domains such as fatigue (P <.0001), thinking (P =.0458), and mobility of lower extremities (P =.0397).  

Related Articles

“To our knowledge, this trial is the largest of any published behavioral or pharmacological fatigue treatment trial in MS to date,” the investigators wrote. Although the study had multiple limitations, including a dropout rate of 19% and the lack of an active control group, the result “provides evidence for the effectiveness of a self-guided, internet-based intervention to reduce fatigue in MS. Interventions such as ELEVIDA may be a suitable low barrier, cost-effective treatment option for MS fatigue.”

Reference

Pottgen J, Moss-Morris R, Wendebourg JM, et al. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis [published online March 16, 2018]. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2017-317463